NCT06520891

"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 90 (estimated)
• Sponsor: Fayoum University · Academic / Other
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: —

Summary

correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests (cholesterol, LDL, HDL and TG...)

Detailed description

This is a prospective study that will carried out in Department of cardiology, Faculty of Medicine, Fayoum University during the period from 1 April 2024 to 1 Juley 2024. The study includes 90 Outpatients Clinic patients who met the inclusion criteria. Patients will provide written informed consent before involving in this study. * we will split the 90 patients into three groups: 1. 30 patients will take statin. 2. 30 patients will take SGLT2i. 3. 30 patients will take both of statin and SGLT2i. * By collecting their blood samples and calculate the serum level of statin by using HPLC and calculate plasma level of SGLT2i by using HPLC as baseline first then after three months to predict the effect of each drug to another one, we will follow their cholesterol, triglyceride, low density lipo-protein and high density lipo-protein and we will also inspect their adverse effects.

Conditions

• 2 Drugs Are Statin and SGLT2i

Interventions

Type	Name	Description
DRUG	Statin and SGLT2i	Statin as atrovastatin SGLT2i as dapagliflozin

Timeline

• Start date: 2024-06-01
• Primary completion: 2025-11-30
• Completion: 2025-12-30
• First posted: 2024-07-25
• Last updated: 2025-09-11

Locations

1 site across 1 country: Egypt